| Name | Title | Contact Details |
|---|
What if you could repair broken genes? That is the question we ask ourselves every day at Editas Medicine. We`re a leading genome editing company focused on translating the power and promise of our proprietary genome editing systems into medicines to help transform the lives of people with genetically-defined diseases. Our goal is to discover, develop, manufacture, and commercialize transformative medicines for a range of serious diseases, including eye diseases, blood diseases, and cancer. We are a vibrant company full of hope, possibilities, and a belief that, working together as One Editas, we can truly revolutionize the development of medicines. We are on an important journey to unlock the full potential of genome editing technology. A journey fueled by our distinct culture, expert team of Editas Medicine `Editors`, and the patients we aspire to help around the world. Connect with us to hear about the tremendous progress and scientific advancements we`ve already made and the next breakthrough on the horizon. If you are ingenious, passionate and resilient, come join the revolution. Repairing broken genes is only the beginning.
Acorda Therapeutics is a publicly traded (NASDAQ: ACOR) biotechnology company whose mission is to develop therapies that restore neurological function and improve the lives of people with neurological disorders. We started our company in 1995 as a network of scientists, physicians and business people with a common belief that sharing ideas and information could lead to innovative medical advances for people with neurological disorders. We have since evolved into a commercial-stage biotechnology company, successfully developing and commercializing important therapies that advance the care of people affected by neurological conditions. We achieve our goals by: • investing in research and development • collaborating closely with the patient, medical and scientific communities • retaining employees with compassion and commitment Acorda has been voted one of the best companies to work for in New York for the past five years in a row, as a result of our dynamic environment, strong corporate culture, significant emphasis on research and development, and a robust product pipeline. We are positioned to be an industry leader, poised for exceptional growth.
Eiger is a biopharmaceutical company focused on the discovery and development of new antiviral agents against novel targets in the treatment of hepatitis. Eiger`s pipeline includes preclinical NCEs from discovery as well repurposed clinical Rx agents shown to possess antiviral activity against Hepatitis C, Hepatitis D, and a wide array of other viruses.
Organogenesis Inc. is a Canton, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Cyagen Biosciences is an emerging and innovative biotechnology company that specializes in custom murine model generation, DNA vector construction and viral packaging services. We also offer a comprehensive catalog of stem cell lines, cell culture reagents and growth factors. Our rapidly expanding services portfolio features VectorBuilder – an online DNA vector construction platform designed to make tedious cloning projects obsolete. Let us provide the knowledge and resources to move your project forward, and get you back to discovery!